Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute	Vaccine, Immunity and Cancer Directorate Standard Operating Procedure	
SOP Title: BCA Protein Assay		
Document ID: 30009	Version	4.0
Page 1 of 18	Supersedes	3.0
Effective Date: 27Sep21	· · ·	

Written by:			
Printed Name:	Title:	Signature/Date:	
Ashley McCormack	Research Associate II		

Approved by:			
Printed Name:	Title:	Signature/Date:	
Troy Kemp	Scientific Manager		
QA Approved by:			
Printed Name:	Title:	Signature/Date:	
Hussain Shaffi	QA Specialist IV		

sponsored by the National Cancer Institute

Vaccine, Immunity and Cancer Directorate Standard Operating Procedure

SOP Title: BCA Protein Assay

Document ID: 30009	Version	4.0	
Page 2 of 18	Supersedes	3.0	
Effective Date: 27Sep21			

1. PURPOSE

1.1. The purpose of this procedure is to detect and quantitate total protein within a sample using the bicinchoninic acid (BCA) colorimetric assay.

2. SCOPE

2.1. This procedure applies to measuring total protein within HPV Virus-like particles (VLP) or biological samples.

3. REFERENCES

- 3.1. F.E. Grubbs, "Procedures for Detecting Outlying Observations in Samples" Technometrics 11:1 pp 1-21 (1969)
- 3.2. Qualification Report (YT16-130-01) for QC1 & QC2 (Developed in-house)
- 3.3. 10009: General Record Review
- 3.4. 15000: Waste Disposal at the Advanced Technology Research Facility
- 3.5. 26000: Biosafety Cabinet (BSC) Use and Maintenance
- 3.6. 26003: Use and Maintenance of a Molecular Devices Plate Reader
- 3.7. 26005: Use and Maintenance of a 2-8°C Refrigerator
- 3.8. 26009: Use and Maintenance of Pipettes
- 3.9. 26014: Use and Maintenance of a Laboratory Convection Incubators
- 3.10. 26020: Use and Maintenance of a Microplate Shaker

4. **RESPONSIBILITIES**

- 4.1. The Research Associate, hereafter referred to as Analyst, is responsible for reviewing and following this procedure, and documenting assay information.
- 4.2. The Scientific Manager or designee is responsible for training personnel in this procedure and reviewing associated documentation.

Vaccine, Immunity and Cancer Directorate Standard Operating Procedure

sponsored by the National Cancer Institute

SOP Title:	BCA Protein Assay
------------	-------------------

Document ID: 30009	Version	4.0
Page 3 of 18	Supersedes	3.0
Effective Date: 27Sep21		

- 4.3. The Quality Assurance Specialist is responsible for quality oversight and approval of this procedure.
- 4.4. Trained personnel perform assay record review per "10009: General Record Review."

5. DEFINITIONS

Term	Definition	
Abs	Absolute Value	
Ave	Average Value	
BCA	Bicinchoninic acid	
BSA	Bovine Serum Albumin	
CI	Confidence Interval	
Conc	Concentration	
CV	Coefficient of Variation (Percent)	
FIO	For Information Only	
ID	Identification	
OD	Optical Density	
RT	Room Temperature	
WR	Working Reagent	

6. REAGENTS, MATERIALS, AND EQUIPMENT

- 6.1. Reagents
 - 6.1.1. BSA Standard, 2 mg/mL Concentration, 10 x 1 mL Ampoules (VWR, Cat # PI-23209 or equivalent)
 - 6.1.2. BSA_QC1, Quality Control #1 (Developed in-house)
 - 6.1.3. BSA_QC2, Quality Control #2 (Developed in-house)
 - 6.1.4. 1X Dulbecco's PBS (DPBS) (Life Technologies, Cat # 14190-235 or equivalent)
 - 6.1.5. Kit, Pierce BCA Protein Assay (VWR, Cat # PI23225 or PI23227)
- 6.2. Consumables
 - 6.2.1. Plate, 96-well, Flat Bottom, Tissue Culture Plate (Thomas Scientific, Cat # 6906A07 or equivalent)

Vaccine, Immunity and Cancer Directorate Standard Operating Procedure

sponsored by the National Cancer Institute

SOP Title: BCA Protein Assay

Document ID: 30009	Version	4.0
Page 4 of 18	Supersedes	3.0
Effective Date: 27Sep21		

- 6.2.2. Plate Sealers, Clear (Thomas Scientific, Cat # 6980A01 or equivalent)
- 6.2.3. Reagent Reservoir (Corning, Cat # 4870 or equivalent)
- 6.2.4. Pipette Tips
- 6.2.5. Serological Pipettes (Ranging from 1 mL to 50 mL)
- 6.2.6. 1.5 mL Tubes, Microcentrifuge, Screw top (VWR, Cat # 10025-726 or equivalent)
- 6.2.7. 1.2 mL Tubes, Polypropylene, Cluster (VWR, Cat # 29442-612 or equivalent)

6.3. Equipment

- 6.3.1. Ampule Snapper/Breaker/Collar, Disposable (VWR, Cat # 66009-125, or equivalent)
- 6.3.2. Class II Biosafety Cabinet (BSC)
- 6.3.3. Convection Oven
- 6.3.4. Microplate Shaker
- 6.3.5. Microplate Reader (Molecular Devices M5 or equivalent)
- 6.3.6. Pipettes (Rainin)
- 6.3.7. Serologic Pipettor

7. HEALTH AND SAFETY CONSIDERATIONS

- 7.1. Proper safety precautions should be taken while working in a laboratory setting. This includes, but is not limited to, proper protective equipment such as lab coats, safety glasses, closed-toe shoes, and non-latex gloves.
- 7.2. When possible, needle-resistant gloves or disposable ampule snapper should be used when breaking open the BSA ampule and disposed of in a sharp's container.
- 7.3. Refer to the respective Safety Data Sheet (SDS) when working with any chemicals.

sponsored by the National Cancer Institute

Vaccine, Immunity and Cancer Directorate Standard Operating Procedure

SOP Title: BCA Protein Assay

Document ID: 30009	Version	4.0
Page 5 of 18	Supersedes	3.0
Effective Date: 27Sep21		

7.4. Refer to "15000: Waste Disposal at the Advanced Technology Research Facility," for waste disposal processes.

8. **PROCEDURE PRINCIPLES**

- 8.1. BCA Protein Assay is used to determine total protein concentration of an unknown sample.
- 8.2. Cu⁺² is reduced to Cu⁺¹ in the presence of protein when in an alkaline medium and is chelated to BCA, leading to absorbency at a wavelength of 562 nm and demonstrating linear correlation to protein values.
- 8.3. A known BSA standard curve is used to confirm protein concentrations and to calculate the unknown sample's protein concentration.
- 8.4. All work should be performed inside a BSC.
- 8.5. Process relevant information is recorded on "30009-01: BCA Data Capture Form."
- 8.6. Every BCA plate layout will include: BSA Standards (serially diluted into a Standard Curve), two positive Quality Control samples (one high OD and one low OD but each falling within the BSA Standard Curve range), and a reagent Blank; each tested in triplicate (see Figure 1 for plate layout).

9. PROCEDURE

- 9.1. Allow Laboratory Convection Incubator to reach temperature, 37 ± 2°C, per "26014: Use and Maintenance of a Laboratory Convection Incubators."
- 9.2. Thaw sample(s) at room temperature (RT) prior to use for at least 20 minutes, until fully thawed.
- 9.3. Label skirt/face of each 96-Flat Bottom plate with Plate Number, Data Reference/Assay Tracking Number, Analyst Initials, and Date. See Attachment 1: 96-Well Plate Skirt Label to properly label plate.
- 9.4. Standard Curve Preparation
 - 9.4.1. Prepare nine dilution tubes and label each tube with vial letter (see Table 1) (may use cluster tubes if desired).
 - 9.4.2. Prepare standard curve dilutions in DPBS.

Verify current version prior to use. Use of a superseded or obsolete document is prohibited.

sponsored by the National Cancer Institute

Vaccine, Immunity and Cancer Directorate Standard Operating Procedure

SOP Title: BCA Protein Assay

Document ID: 30009	Version	4.0
Page 6 of 18	Supersedes	3.0
Effective Date: 27Sep21		

- 9.4.2.1. Mix vial of BSA Standard by inversion, then tap liquid from lid to bottom of vial before opening ampule.
- 9.4.2.2. Carefully open an ampule of the BSA standard. Use needleresistant gloves, or use an ampule snapper, to break lid of ampule on the line etched around top of vial neck.

Note: Dispose of glass top in a plastic sharps container.

9.4.2.3. Prepare BSA standard curve dilutions per Table 1.

Table 1: BSA Standard Curve Dilutions

Vial	Volume of DPBS (µL)	Volume and Source of Stock (µL)	Final BSA Concentration (µg/mL)
A	0	300 of Stock	2000
В	125	375 of Stock	1500
С	325	325 of Stock	1000
D	175	175 of Vial B Dilution	750
E	325	325 of Vial C Dilution	500
F	325	325 of Vial E Dilution	250
G	325	325 of Vial F Dilution	125
Н	400	100 of vial G Dilution	25
	400	0	0 (Blank)

- 9.5. Sample Preparation
 - 9.5.1. Dilute each sample so the expected protein concentration falls within the standard curve.
 - 9.5.1.1. Three separate dilution factors will be prepared for each sample.
 - 9.5.1.2. A minimum of 100 µL total volume will be required for each sample Dilution Factor, as each will be plated in triplicate.
 - 9.5.1.3. Initial sample dilutions are recommended in Table 2 but may be adjusted based on the expected protein concentration.

Table 2: Recommended Initial Sample Dilutions

Description	Starting Dilution Factor	Sample Volume	DPBS
Dilution 1	1:2	100 µL	100 µL
Dilution 2	1:4	100 μL of Dilution 1	100 µL
Dilution 3	1:8	100 µL of Dilution 2	100 µL

Verify current version prior to use. Use of a superseded or obsolete document is prohibited.

sponsored by the National Cancer Institute

Vaccine, Immunity and Cancer Directorate Standard Operating Procedure

SOP Title: BCA Protein Assay

Document ID: 30009	Version	4.0				
Page 7 of 18	Supersedes	3.0				
Effective Date: 27Sep21						

9.5.2. Add 25 µL of Standards, BSA_QC1, BSA_QC2, Blanks, and Samples to the plate in triplicate. Refer to Attachment 2 for plate layout.

Note: Unused sample wells remain empty throughout procedure.

9.6. Preparation and Addition of Working Reagent (WR)

Note: A volume of 200 μ L of WR is required per well used in assay; including standards and controls. To test one 96-well plate, 25 mL total of WR is required.

- 9.6.1. Mix 50 parts BCA Reagent A with 1-part BCA Reagent B from kit to make WR.
 - 9.6.1.1. For example, combine 25 mL of Reagent A with 500 μL Reagent B for a total of 25.5 mL WR.

Note: WR should be a clear green color when both reagents are mixed.

- 9.6.2. Add 200 µL of WR to all wells used, being careful not to touch pipette tip to liquid already present in plate.
- 9.7. Plate Incubation
 - 9.7.1. Once all standards, controls, samples, and WR have been added to plate, cover plate with plate sealer and mix on a Plate Shaker at 250-350 rpm for approximately 30 seconds per "26020: Use and Maintenance of a Microplate Shaker."

Figure 1. Plate Map for loading standards, controls, blank, and samples.

	1	2	3	4	5	6	7	8	9	10	11	12
Α	2	2000 µg/m	L	0 µ	g/mL (Bla	ank)	BSA_QC1		BSA_QC2			
В	1500 µg/mL			Sample 1, Dilution 1			Sample 3, Dilution 1		tion 1	Samp	ole 5, Dilu	tion 1
С	1	000 µg/m	L	Samp	ole 1, Dilu	tion 2	Sample 3, Dilution 2		Sample 5, Dilution 2		tion 2	
D	ī	750 µg/ml	L	Samp	ample 1, Dilution 3		Sample 3, Dilution 3			Sample 5, Dilution 3		
Е	500 µg/mL			Samp	Sample 2, Dilution 1		Samp	ole 4, Dilu	tion 1	Samp	ole 6, Dilu	tion 1
F	2	250 µg/ml	L	Samp	Sample 2, Dilution 2		Samp	Sample 4, Dilution 2		Sample 6, Dilu		tion 2
G		125 µg/ml	L	Samp	mple 2, Dilution 3 Sample			ole 4, Dilu	tion 3	Samp	ole 6, Dilu	tion 3
Н		25 µg/mL		Samp	ole 7, Dilu	tion 1	Samp	ole 7, Dilu	tion 2	Samp	ole 7, Dilu	tion 3

Verify current version prior to use. Use of a superseded or obsolete document is prohibited.

Vaccine, Immunity and Cancer Directorate Standard Operating Procedure

sponsored by the National Cancer Institute

SOP Title: BCA Protein Assay

Document ID: 30009	Version	4.0
Page 8 of 18	Supersedes	3.0
Effective Date: 27Sep21		

9.7.2. Incubate plate at $37 \pm 2^{\circ}$ C for 30 ± 5 minutes in Convection Incubator.

Note: Do not use CO_2 Incubator as this could introduce contamination to Incubator.

9.7.3. Remove plate from Convection Incubator and allow plate to equilibrate to RT for 5 ± 1 minutes.

9.8. Plate Reading

- 9.8.1. During RT incubation (step 9.7.2), turn on Plate Reader and open "BCA Template" Protocol file (.sprx) located under O:\HSL\HSL_Templates\BCA in SoftMax Pro.
- 9.8.2. Enter Sample IDs (HPV-Type, Sample Description, and Lot Number when applicable), Dilution Factors, and background information into template.
- 9.8.3. SoftMax Pro is connected to Plate Reader when instrument tab in the top left corner of the screen has a green checkmark over picture of the instrument.
- 9.8.4. Once RT incubation completed, remove plate sealer, place plate into Plate Reader tray with Plate Adapter in place.
- 9.8.5. Select corresponding assay plate under the template-specific Navigation Tree on the left of the screen, then select "Read" on the screen.
- 9.8.6. Name data file as follows:

9.8.7. Save file as a data file (.sdax) in O:\HSL\Plate Reader\Raw Data Files\BCA.

10. SYSTEM SUITABILITY

10.1. BSA_QC1 and BSA_QC2 Controls Acceptance Criteria

10.1.1. Three replicates of each in-house developed control are run on every plate.

Note: Refer to corresponding notebook for specific acceptance criteria from the established Qualification Report (currently YT16-130-01) or discuss with Scientific Manager.

Verify current version prior to use. Use of a superseded or obsolete document is prohibited.

[&]quot;Data Reference/Assay Tracking Number_BCA_DDMMMYYAnalyst Initials" (L0001003_BCA_20MAY17ABC)

sponsored by the National Cancer Institute

Vaccine, Immunity and Cancer Directorate Standard Operating Procedure

SOP Title: BCA Protein Assay

Document ID: 30009	Version	4.0
Page 9 of 18	Supersedes	3.0
Effective Date: 27Sep21		

- 10.1.2. The BSA_QC1 and BSA_QC2 Controls must have a percent CV of \leq 20%.
- 10.1.3. One well may be masked within the replicates if it does not meet percent CV criteria. See Attachment 3: Outlier Test: Grubb's Test for Triplicates for outlier assessment to indicate which Optical Density (OD) value between triplicates is masked for calculation.

10.2. Blank Acceptance Criteria

- 10.2.1. Three replicates of 1X DPBS Blank Control are run on every plate.
- 10.2.2. The Blank Control Average must have an average absorbance reading below the 25 μg/mL BSA standard. (See section 10.3)

Note: Up to one well may be masked if considered contaminated.

10.3. 2000 µg/mL and 25 µg/mL BSA Standard Curve Acceptance Criteria

- 10.3.1. Three replicates of each <u>2000 μg/mL and 25 μg/mL</u>BSA Standards are run on every plate.
 - 10.3.1.1. 2000 μg/mL BSA Standard is also referred to as the **Top of the Standard Curve**.
 - 10.3.1.2. 25 µg/mL BSA Standard is also referred to as the **Bottom of the Standard Curve**.
- 10.3.2. The percent CV for the two standard replicates of $2000 \mu g/mL$ and $25 \mu g/mL$ only must be $\leq 15 \%$ for the data to be considered valid.
- 10.3.3. One well may be masked within this range if it does not meet the percent CV criteria. See Attachment 3: Outlier Test: Grubb's Test for Triplicates for outlier assessment to indicate which Optical Density (OD) value between triplicates is masked for calculation.

10.4. Remaining BSA Standard Curve Acceptance Criteria

- 10.4.1. Three replicates of <u>1500 μg/mL to 125 μg/mL</u> BSA Standards are run on every plate.
- 10.4.2. The percent CV between the remaining standard replicates of $1500 \mu g/mL$ to $125 \mu g/mL$ must be $\leq 10\%$ for the data to be considered valid.

sponsored by the National Cancer Institute

Vaccine, Immunity and Cancer Directorate Standard Operating Procedure

SOP Title: BCA Protein Assay

Document ID: 30009	Version	4.0
Page 10 of 18	Supersedes	3.0
Effective Date: 27Sep21		

10.4.3. One well may be masked within this range if it does not meet the percent CV criteria. See Attachment 3 for outlier assessment to indicate which Optical Density (OD) value between triplicates is masked for calculation.

10.5. Standard Curve

- 10.5.1. Only one full standard concentration (three wells) may be masked in the standard curve range.
- 10.5.2. If more than one standard needs to be masked, then the whole plate needs to be retested.
- 10.5.3. The same standard preparation may be used for the retest if made in the same day; otherwise, a new set of standards needs to be created.
- 10.5.4. If the standards fail system suitability on the retest, then a new set of standard dilutions will need to be prepared prior to testing a third time.

11. QUALITY CONTROL

- 11.1. Two positive control samples (BSA QC 1 and BSA QC 2) will be added to each plate in triplicate.
- 11.2. Document the QC ranges on 30009-01 and indicate whether the QC samples passed or failed.
- 11.3. Log the QC data in the BCA QC Trending file.
- 11.4. If either of the QC samples is out of range, then the whole plate is repeated. A new set of QC samples will be used on the retest.
- 11.5. If the same control fails on two subsequent runs, the control trending data is reviewed by the Scientific Manager and further testing guidance is provided by the Scientific Manager or designee.

12. DATA ANALYSIS

- 12.1. Sample Results
 - 12.1.1. At least one of the Sample Dilutions tested must fall within the BCA Standard Curve at concentrations of <u>1500 μg/mL to 125 μg/mL</u> for the results to be valid.

Verify current version prior to use. Use of a superseded or obsolete document is prohibited.

sponsored by the National Cancer Institute

Vaccine, Immunity and Cancer Directorate Standard Operating Procedure

SOP Title: BCA Protein Assay

Document ID: 30009	Version	4.0
Page 11 of 18	Supersedes	3.0
Effective Date: 27Sep21	·	

- 12.1.1.1. If not, repeat the Sample testing at a different set of dilutions, where the protein concentration for at least one of the sample dilutions falls within the standard curve.
- 12.1.2. The percent CV within the triplicates of each Sample Dilution must be $\leq 20\%$ for the data to be considered valid.
 - 12.1.2.1. If any triplicates have a percent CV of >20%, see Attachment 3 for outlier assessment to indicate which OD value between triplicates is masked for calculation.
- 12.1.3. If any of these criteria are not met, repeat the sample test.
- 12.1.4. Following Data Analysis, print data file and attach to 30009-01 form. Deselect Audit Trail from Printer Preferences if not needed.

13. ATTACHMENTS

- 13.1. Attachment 1: 96-Well Plate Skirt Label
- 13.2. Attachment 2: Plate Layout
- 13.3. Attachment 3: Outlier Test: Grubb's Test for Triplicates
- 13.4. Attachment 4: 30009-01: BCA Data Capture Form

14. **REVISION HISTORY**

Version	Change	Reason
2.0	Update forms to include incubation times at 37C Tighten Standard Control %CV Ranges. Update Forms.	Need to tighten %CV Ranges to align assay with practices/results. General updates to clarify what information is expected.
3.0	 Update to new SOP format. Forms now separate. Minor grammar and formatting changes throughout document. Removed HSL_GL_002, HSL_GL_003, HSL_GL_004, HSL_GL_005, HSL_GL_006, HSL_GL_007, HSL_GL_008, HSL_GL_009, HSL_GL_010, 	 Consistency between procedures. Ease of use. Clarification. Not referenced in procedure. New reference for procedure.

sponsored by the National Cancer Institute


Vaccine, Immunity and Cancer Directorate Standard Operating Procedure

SOP Title: BCA Protein Assay						
Document ID: 30009	Version	4.0				
Page 12 of 18	Supersedes	3.0				
Effective Date: 27Sep21						

 HSL_EQ_002 from References section. Added reference to F.E. Grubbs publication. 4. Split Reagents, Equipment and Materials into three subsections. Added oven, plate shaker, plate reader, pipettes, pipette tips, reagent reservoir, serological pipettes and pipette. 4. Consistency between procedures clarification. 			
Materials into three subsections.clarification.Added oven, plate shaker, plate reader, pipettes, pipette tips, reagent reservoir, serologicalclarification.		Grubbs publication.	
		Materials into three subsections. Added oven, plate shaker, plate reader, pipettes, pipette tips,	
5. Changed "Background" section to clarification.		pipettes and pipette. 5. Changed "Background" section to	5. Consistency between procedures, clarification.
Procedure Principles in new format. Added reference that all work performed in BSC, process related		Added reference that all work performed in BSC, process related	
		6. Removed ATRF, FME, SOP and added BCA and ID to definitions	-
7. Section 9, added step to label plate. 7. Reflect current practice.			•
			•
9. Added sample thaw step in sample 9. Reflect current practice. preparation section.			
10. Added note that unused sample wells remain empty, and not to use CO2 incubator in WR section.		10. Added note that unused sample wells remain empty, and not to use	10. Clarification.
11. Added outlier calculation step to section 10 and as Attachment 2.11. Update to process.		•	11. Update to process.
12. Updated well masking for blanks in Section 10.			12. Update to process.
13. Added reference for where to find 13. Clarification. control range.			13. Clarification.
14. Rephrased section 11. 14. Clarification.			14. Clarification.
			1. Consistency between procedures,
4.0 2. Updated System Suitability, Quality clarification.	40		
Control, and Data Analysis Section 2. Clarification and reflect GCLP practice	1.0	Control, and Data Analysis Section	

Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute	Vaccine, Immunity and Cancer Directorate Standard Operating Procedure			
SOP Title: BCA Protein Assay				
Document ID: 30009	Version	4.0		
Page 13 of 18	Supersedes	3.0		
Effective Date: 27Sep21	· · ·			

Attachment 1: 96-Well Plate Skirt Label



Frederick National Laboratory
for Cancer Research
sponsored by the National Cancer InstituteVaccine, Immunity and Cancer Directorate
Standard Operating ProcedureSOP Title: BCA Protein AssayDocument ID: 30009Version4.0Page 14 of 18Supersedes3.0Effective Date: 27Sep21Version4.0

Attachment 2: Plate Layout

	1	2	3	4	5	6	7	8	9	10	11	12
Α	2	2000 µg/m	L	0 μg/mL (Blank)		I	BSA_QC	1	BSA_QC2			
В	1	500 µg/m	L	Sample 1, Dilution 1		Samp	ole 3, Dilu	ition 1	Sample 5, Dilution 1			
С	1	000 µg/m	L	Samp	ole 1, Dilu	ition 2	Sample 3, Dilutio		ition 2	Samp	Sample 5, Dilution 2	
D		750 µg/ml	L	Sample 1, Dilution 3		Sample 3, Dilution 3			Sample 5, Dilution 3			
Е		500 µg/ml	L	Sample 2, Dilution 1		Samp	ole 4, Dilu	ition 1	Samp	ole 6, Dilu	ition 1	
F	:	250 µg/mL		Samp	mple 2, Dilution 2		Sample 4, Dilution 2		Sample 6, Dil		ition 2	
G		125 µg/ml	L	Samp	Sample 2, Dilution 3		Sample 4, Dilution 3		Sample 6, Dilution		ition 3	
Н		25 µg/mL	-	Sample 7, Dilution 1			Samp	ole 7, Dilu	ition 2	Samp	ole 7, Dilu	ition 3

Attachment 3: Outlier Test: Grubb's Test for Triplicates (Standard Deviation Method)

- 1. Rank the three values from lowest to highest: X1, X2, X3.
- 2. Calculate the Mean (M) and Standard Deviation (SD).
 - a. M = (X1 + X2 + X3) / 3
 - b. $SD = \sqrt{((X1-M)^2 + (X2-M)^2 + (X3-M)^2)/3)}$
- Calculate the Grubb's Test (GT) value using calculation below if the HIGHEST value (X3) is the suspected outlier.

GT = (X3-M) / SD

4. Calculate the GT value using calculation below if the LOWEST value (X1) is the suspected outlier.

GT = (M-X1) / SD

5. If the GT is GREATER THAN the value in the table below, the suspected value IS an outlier.

N # replicates	95% CI	97.5% CI	99% CI
3	1.15	1.15	1.15

Verify current version prior to use. Use of a superseded or obsolete document is prohibited.

Frederick National Laboratory	
for Cancer Research	

Vaccine, Immunity and Cancer Directorate Standard Operating Procedure

sponsored by the National Cancer Institute

SOP Title: BCA Protein Assay		
Document ID: 30009	Version	4.0
Page 15 of 18	Supersedes	3.0
Effective Date: 27Sep21		

Attachment 4: 30009-01: BCA Data Capture Form

HPV Serology Laboratory Standard Operating Procedure Form Frederick National Laboratory for Cancer Research ored by the National Cancer In Form Title: BCA Data Capture Form Document ID: 30009-01 Version 4.0 Associated SOP: 30009 Effective Date: 27Sep21 Supersedes Version: 3.0 Page 1 of 4 Equipment Equipment Description Equipment ID Calibration Due Date BSC BHSL_007 BHSL_008 Other: Convection Oven □ HSL_025 □ Other: □ HSL_030 □ HSL_031 □ Other: □ Other: Microplate Shaker Microplate Reader □ HSL_018 □ Other Pipette: μL PIP n N/A Pipette: μL PIP □ N/A Pipette: PIP μL □ N/A Pipette: μL PIP_ n N/A Pipette: μL PIP. Reagents Lot Number Expiration Date Reagent DPBS BCA Kit □ N/A BSA Standard, 2 mg/mL 🗆 N/A BSA_QC1 D N/A BSA_QC2 □ N/A Sample Identification UN/A (No samples prepared) Sample Number HPV Type Sample Description Data Reference/Unique Identifier HPV-16 L0001001 Pooled fractions 3-5, T22 example □ N/A 2 □ N/A 3 □ N/A N/A □ N/A □ N/A □ N/A

Verify current version prior to use. Use of a superseded or obsolete document is prohibited.

This document contains confidential and proprietary information. Do not copy or distribute without prior, written permission.

sponsored by the National Cancer Institute

Vaccine, Immunity and Cancer Directorate Standard Operating Procedure

SOP Title: BCA Protein Assay

Document ID: 30009	Version	4.0
Page 16 of 18	Supersedes	3.0
Effective Date: 27Sep21		

Frederi	ck National La for Cance sponsored by the Natio	r Research	St	HPV Serology Laboratory andard Operating Procedum Form
Form Title:	BCA Data Capt	ure Form		
Document	ID: 30009-01		Version:	4.0
Associated	SOP: 30009		Effective Date:	27Sep21
Supersede	es Version:	3.0		Page 2 of 4
Sample Pr	eparation 🗆 N/A (N	lo samples prepared)		
Sample Number	Starting Dilutio	n	olume (µL)	DPBS Volume (µL)
	1.			
1 □ N/A	2.		μL of Dilution 1	
	3.		μL of Dilution 2	
2	1.			
□ N/A	2.		µL of Dilution 1	
	3.		µL of Dilution 2	
3	1.		10 (10-00 (10))	
□ N/A	2.		µL of Dilution 1	
	3. 1.		µL of Dilution 2	
4	2.		µL of Dilution 1	
□ N/A	3.		μL of Dilution 2	
	1.		,	
5	2.		µL of Dilution 1	
⊓ N/A	3.		µL of Dilution 2	
	1.			
6 □ N/A	2.		µL of Dilution 1	
	3.		µL of Dilution 2	
	1.			
7 □ N/A	2.		μL of Dilution 1	
	3.		µL of Dilution 2	
Incubation	Times			
Co	ondition	Start Time	End Time	Total Time (Min)
	37°C 5 minutes			
RT Eq	uilibration minutes		Read Start Time:	
		ion prior to use. Use of a su		ment is prohibited. stribute without prior, written

sponsored by the National Cancer Institute

Vaccine, Immunity and Cancer Directorate Standard Operating Procedure

SOP Title: BCA Protein Assay

Document ID: 30009	Version	4.0
Page 17 of 18	Supersedes	3.0
Effective Date: 27Sep21		

	on Cancer Research d by the National Cancer institute		s	HPV Serology Laboratory itandard Operating Procedure Form
Form Title: BCA Da	ta Capture Form			
Document ID: 3000	9-01		Version:	4.0
Associated SOP: 30	009		Effective Date:	27Sep21
Supersedes Versior	n: 3.0			Page 3 of 4
Data File Name:				
System Suitability R				
Curve	Range		ss, Fail	
2000 µg/mL	% CV ≤ 15%	🗆 Pa	ss ⊑ Fail	
1500 µg/mL	% CV ≤ 10%	🗆 Pa	ss ⊑ Fail	
1000 µg/mL	% CV ≤ 10%	🗆 Pa	ss 🗆 Fail	
750 µg/mL	% CV ≤ 10%	🗆 Pa	ss ⊑ Fail	
500 µg/mL	% CV ≤10%	🗆 Pa	ss ⊑ Fail	
250 µg/mL	% CV ≤ 10%	🗆 Pa	ss ⊑ Fail	
125 µg/mL	% CV ≤ 10%	🗆 Pa	ss ⊑ Fail	
25 μg/mL	% CV ≤ 15%	🗆 Pa	ss 🗆 Fail	
0 μg/mL (Blank)	Abs Value < 25 µg/mL STD	🛛 Pa	ss 🗆 Fail	
QC Description	Range		Reported Result	Pass, Fail
BSA_QC1	% CV ≤ 20%			🗆 Pass 🗆 Fail
	Conc. Range: (µg/mL)			🗆 Pass 🗆 Fail
BSA_QC2	% CV ≤ 20%			□ Pass □ Fail
DOA_QUZ	Conc. Range: (µg/mL)			□ Pass □ Fail

sponsored by the National Cancer Institute

Vaccine, Immunity and Cancer Directorate Standard Operating Procedure

SOP Title: BCA Protein Assay

Document ID: 30009	Version	4.0
Page 18 of 18	Supersedes	3.0
Effective Date: 27Sep21		

Form Title:	BCA Data Captu	re Form		
Document II	D: 30009-01		Version:	4.0
Associated S	SOP: 30009		Effective Date:	27Sep21
Supersedes	Version:	3.0	F	Page 4 of 4
Sample Res	sults 🗆 N/A (No samp	alos proparad)		
Sample Sample Number		esult (µg/mL) *	% CV of Reported Results (<i>Range</i> ≤ 20%)	Pass, Fail, FIO, N/A
1 □ N/A			(····· v · ···· v	□ Pass □ Fail □ FIO □ N/
2 □ N/A				□ Pass □ Fail □ FIO □ N/
3 □ N/A				□ Pass □ Fail □ FlO □ N/
4 □ N/A				🛛 Pass 🗆 Fail 🗆 FIO 🗆 N/
5 □ N/A				⊔ Pass ⊔ Fail ⊔ FIO ⊔ N//
6 ⊔ N/A				🗆 Pass 🗆 Fail 🗆 FIO 🗆 N/
7 □ N/A				🗆 Pass 🗆 Fail 🗆 FIO 🗆 N/
Comments:		rve, that pass % CV crite	rna	
			rna	